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Abstract. Aberrant neovascularization supports nutrients and 
the oxygen microenvironment in tumour growth, invasion 
and metastasis. Recapitulation of functional microvascular 
structures in vitro could provide a platform for the study of 
vascular conditions. Sulforaphane (SFN), an isothiocyanate, 
has been reported to possess chemopreventive properties. In 
the present study, the effects of SFN on cell proliferation and 
tubular formation have been investigated using endothelial 
cells (ECs) and pericytes in coculture. SFN showed a dose-
dependent inhibition on the growth of ECs and pericytes with 
IC50 values 46.7 and 32.4 µM, respectively. SFN (5-20 µM) 
inhibited tube formation in a 3D coculture although a lower 
dose (1.25 µM) promoted 30% more endothelial tube forma-
tion than control. Moreover, SFN affected intercellular 
communication between ECs and pericytes via inhibition of 
angiogenic factor such as vascular endothelial growth factor 
(VEGF) expression in pericytes. However, the expression of 
its receptor (VEGFR-2) was found significantly increased 
in ECs. These effects were associated with downregulation 
of prolyl hydroxylase domain-containing protein 1 and 2 
(PHD1/2) and activation of hypoxia-inducible factor-1 (HIF) 
pathway by SFN. Furthermore, thioredoxin reductase-1 was 
also upregulated by SFN treatment, suggesting that anti-
oxidant and redox regulation are involved in angiogenesis. 
Taken together, the results of the present study suggest that 
SFN differentially regulates endothelial cells and pericytes 
disrupting their interplay through the VEGF-VEGFR signal-
ling pathway. Anti-angiogenesis property of SFN indicates 
that it has potential role as an anticancer agent.
Introduction
Angiogenesis, the growth of new capillary blood vessels, is a 
normal and vital process in growth, development and wound 
healing. However, it is also a fundamental step in the growth of 
tumours. Nutrients and oxygen, supplied by the blood vessels 
into the tumours, are essential for the growth and progression 
of malignant tumours beyond the size of 1-2 mm3 (1). Newly 
formed blood vessels can facilitate cells escaping through 
leakage from primary tumour sites to metastasize, the major 
cause of mortality for cancer patients. Anti-angiogenesis has 
been recognized as valuable therapy in treatment of various 
metastatic cancers since the theory was first proposed by 
Folkman (2,3). Tumour angiogenesis is believed to be regulated 
by the interactions between pro-angiogenic and anti-angio-
genic factors in the tumour microenvironment (4). Angiogenic 
response is a dynamic process requiring a series of fine-tuned 
angiogenic signalling and molecular events. Hypoxia is the 
common inducer of angiogenesis in the core of large tumours 
stimulating the release of pro-angiogenic factors to promote 
endothelial cell proliferation, migration, differentiation and 
self-assembly into vascular-like structures. Subsequently, 
perivascular cells are recruited to form mature and stable 
vessels (5).
The interaction between endothelial cells (ECs) and 
pericytes (PVCs) has gained increasing attention as a central 
process in the regulation of blood microvascular structures 
as well as in their stabilization and maturation. Aberrant 
interplays between the two cell types have been observed 
in a multitude of human pathological conditions, including 
cancer angiogenesis (6). Targeting one cell type, either ECs 
or PVCs may produce limited effects. The most effective 
therapies will probably involve targeting multiple mediators, 
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and will require improving the efficiency of drug delivery 
to the tumour microenvironment (7,8). Therefore, improving 
the therapeutic response will require consideration of various 
signalling pathways and cell types involved in the vascular 
component of cancer.
Hypoxia-inducible factor-1 (HIF-1α) dependent hypoxia-
induced response is tightly controlled by HIF-prolyl 
hydroxylase domain (PHD) which targets HIF-1α for degra-
dation. Oxygen-dependent PHDs negatively regulate HIFs 
and, crucially, confer its oxygen sensitivity. In the presence of 
oxygen, PHD2 hydroxylates HIF-1α on two specific proline 
residues, which results in its destruction. In hypoxia, PHD2 is 
missing its co-substrate (oxygen), rendering it inactive. HIF-1α 
then becomes stabilized, and results in the upregulation of 
angiogenic factors such as vascular endothelial growth factor 
(VEGF), fibroblast growth factor (FGF)-2 and angiopoietin-2 
thereby promoting neovascularization. Hypoxia also inacti-
vates PHDs, causing accumulation of HIF-1α which in turn 
further transactivates PHDs. This feedback loop ensures the 
homeostasis of HIF-1α activity caused by hypoxia (9,10).
After VEGF is released from tumour cells, it binds to two 
cognate VEGF receptors, VEGF receptor 1 (VEGFR1) and 
VEGF receptor 2 (VEGFR2/KDR/flk-1), which are expressed 
on local vascular ECs (11). Signalling through VEGFR1/2 
drives the process of angiogenesis, which involves dissolu-
tion of the vascular basement membrane, endothelial cell 
proliferation and formation of new blood vessels (12). The 
binding to VEGF receptor is a crucial step in initiation of EC 
proliferation, migration and differentiation during angiogen-
esis (13,14). The VEGF signalling system has been suggested 
as a highly ‘druggable’ target and potent inhibitors of the 
VEGF signalling pathway have been used clinically including 
bevacizumab, sunitinib and sorafeib (15-17). To date, targeting 
the HIF/VEGF-VEGFR axis has been a promising strategy for 
cancer therapy (18). Anti-VEGF-VEGFR therapies may also 
have immunological effects (19). Since HIF signalling contrib-
utes to the acquisition of resistance against anti-VEGF therapy, 
the combined blockade of VEGF and HIF-1α is being explored 
as a cancer treatment strategy (5). Despite the indisputable 
success of anti-angiogenic drugs in the clinical treatment for 
some advanced solid cancers, there are difficulties with regard 
to the control of the activities of these drugs and of the identi-
fication of patients who are sensitive to them (20).
Epidemiological studies have demonstrated that cruci-
ferous vegetables can reduce the risk of various types of 
cancers in humans (21,22). Sulforaphane (SFN) is one of 
the most extensively studied isothiocyanates (ITCs) from 
broccoli and cauliflower. SFN has been found to suppress 
tumour cell growth through multiple molecular mechanisms 
including induction of cell cycle arrest and apoptosis in 
many types of tumour cells (23-26). SFN has been shown to 
inhibit ECs proliferation via apoptosis and autophagy (27-29) 
and suppress VEGF and MMP-2 expression (30,31), the 
latter being associated with the inhibition of FOXO1/AKT 
pathways (32). Moreover, SFN is a known inducer of both 
thioredoxin reductase (TrxR1) and thioredoxin (26,33), 
which are involved in inflammation, apoptosis, angiogenesis, 
embryogenesis and cardiovascular disease involved in angio-
genesis (34). The molecular mechanisms of SFN suppression 
of angiogenesis, in particular the effects on signalling 
pathways between ECs and pericytes in response to SFN 
treatment, are not fully understood. In the present study a 
coculture of primary human umbilical vein endothelial cells 
(HuVECs) and pericytes in a 3D collagen gel model were 
used to dissect the mechanism by which SFN interacts with 
crosstalk between these two key cell types in angiogenesis. 
understanding the interactions between HuVECs and peri-
cytes under SFN treatment may contribute to the development 
of novel agents in anti-angiogenetic therapy.
Materials and methods
Reagents. SFN (4-methylsulfinylbutyl isothiocyanate) was 
purchased from Toronto Research Chemicals, Inc. (North York, 
ON, Canada). High concentration rat tail type-I collagen solu-
tion and purified mouse anti-human CD31/PECAM (555444) 
antibody were both purchased from BD Biosciences (Oxford, 
uK). Polyclonal donkey anti-mouse Cy3 was purchased from 
Abcam (Cambridge, uK). Growth factors PDGF-BB and 
bFGF were obtained from Gibco/Life Technologies (Paisley, 
uK). The primary antibodies against HIF-1α (ab2185), VEGF 
(sc7269), Flk1 (sc6251), TrxR1 (sc20147 were purchased 
from Santa Cruz Biotechnology (Heidelberg, Germany). 
The primary antibodies against PHD1 (ab80361) and PHD2 
(ab83560) were purchased from Abcam. Secondary antibodies 
were from Santa Cruz Biotechnology. siRNA for TrxR1 and 
AllStars (AS) negative control were all purchased from Qiagen 
(West Sussex, uK). Electrophoresis and western blotting 
supplies were obtained from Bio-Rad Laboratories (Hemel 
Hempstead, uK) and the chemiluminescence kit was from GE 
Healthcare (Little Chalfont, uK).
Cell culture. HuVECs were obtained from TCS Cellworks 
and used between passages 2 and 8 for all experiments. The 
cells were grown in plastic flasks pre-treated with 10 µg/ml 
type-I collagen (BD Biosciences) in phosphate-buffered saline 
(PBS) for 30 min in 37˚C incubator. Endothelial growth 
medium-EGM2 (C22011; PromoCell, Birmingham, UK) 
with supplements was used as culture medium for HuVECs 
according to the manufacturer's protocols. Murine perivas-
cular cells (PVC) were isolated as previously described and 
used between passages 32 and 38 (35). Pericytes were routinely 
incubated in Dulbecco's modified Eagle's medium (DMEM) 
containing 10% fetal bovine serum (FBS). All cells were 
incubated at 37˚C in 95% humidified air containing 5% CO2.
Cell viability assay. The MTT assay was used to examine the 
toxicity of SFN in HuVECs and pericytes. Cells were seeded in 
96-well plates and cultured in an incubator at 37˚C to ~70-80% 
confluence. Cultured cells were treated with concentrations 
(1.25-160 µM) of SFN or DMSO (0.1% as control) for 24 h 
with four replicate wells per treatment. After all treatments, 
the medium was removed and fresh medium (100 µl) was 
added together with 10 µl MTT solution (5 mg/ml), then incu-
bated at 37˚C for 1 h to allow the MTT to be metabolized. The 
formazan produced was re-suspended in 100 µl of dimethyl 
sulfoxide (DMSO)/well. The final absorbance in the wells 
was quantified using a microplate reader (BMG Labtech Ltd., 
Aylesbury, uK) at a test wavelength of 570 nm and a reference 
wavelength of 670 nm. Viability of treated cells was expressed 
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as a percentage of control as follows: (A570 nm-A670 nm) 
sample/(A570 nm-A670 nm) control x 100. The IC50 was 
determined using CalcuSyn software version 2.0 (Biosoft, 
Cambridge, uK).
3D co-culture in collagen gel. Capillary-like tube formation 
in 3D collagen matrices of co-culture with HuVEC and peri-
cytes was used to test the angiogenic effects of SFN. Collagen 
type I gels (2 mg/ml) were prepared in 1X DMEM medium 
from concentrated rat tail type I collagen solution (>8 mg/ml 
in 0.02 M acetic acid; BD Biosciences) at 4˚C, supplemented 
with final concentrations of 2% FBS, 22.5 mM NaHCO3, 1 mM 
sodium pyruvate and neutralized with 0.1N NaOH according 
to the supplier's instructions. Cells were trypsinised, washed 
with PBS, counted and desired cell numbers were collected by 
centrifugation. Cells were suspended in the collagen I gel solu-
tion at 4˚C and 400 µl suspension added per well into 24-well 
plates. After an initial incubation at 37˚C for 20 min, 400 µl 
EGM2 culture medium containing SFN (0.6-20 µM) or 0.1% 
DMSO (control) was added to solidified collagen I gels with 
supplements to achieve final concentrations of 10 ng/ml for 
VEGF and PDGF, respectively, and 250 µg/ml ascorbic acid 
phosphate. Typical experiments contained 2.5x105 HuVEC 
and/or 0.5x105 PVC/well, unless otherwise stated. Medium 
was changed every 24 h and cultures were maintained for up 
to 5 days.
Immunostaining of HUVEC-pericyte coculture model. 
Immunohistochemical analyses of cell cultures were performed 
as described by Brachvogel et al (36) and Zhou et al (37). 
Whole mount immunohistochemistry of 3D collagen cultures 
was performed as described by Bader et al (38). Briefly, gels 
were washed in PBS, fixed with 80% methanol/20% DMSO 
for 30 min at 20˚C (or 16 h at 4˚C), then rehydrated in 50% 
methanol/PBS, 20% methanol/PBS and PBS-T (PBS, 0.1% 
Tween-20) for 1 h each and then incubated with blocking buffer 
(10% FBS, 5% BSA in PBS) for 2-4 h at room temperature or 
16 h at 4˚C. Gels were incubated with primary antibodies in 
blocking buffer for 16 h at 4˚C and then washed 7 times for 1 h 
each in TBS-T (TBS, 01% Tween-20) followed by incubation 
with fluorescently labelled secondary antibodies in blocking 
buffer for 2-16 h and then washed again as described above. 
After nuclear staining, samples were mounted in Gelvatol and 
examined by fluorescence microscopy (SteREO LumarV12 
and Axioplan2; Carl Zeiss, Oberkochen, Germany). Pictures 
of fluorescent signals were captured by a black-white camera 
and colour-coded by AxioVision software (version 4.5).
Western blot analysis of protein expression. HuVECs and 
PVC cells were treated with SFN (1-20 µM) or DMSO (0.1% 
as control) at 70-80% confluence. Total protein was extracted 
by washing cells twice with ice-cold PBS and harvested by 
scraping in 20 mM Tris-HCl (pH 8.0), 150 mM NaCl, 2 mM 
EDTA, 10% glycerol, 1% Nonidet P-40 (NP-40) containing 
mini-complete proteinase inhibitor. The cell suspension/lysate 
was placed in an ice bath for 20 min and then centrifuged at 
12,000 x g for 15 min at 4˚C. Protein concentrations were 
determined using the Brilliant Blue G dye-binding assay 
of Bradford using BSA as a standard. Equivalent aliquots 
of protein were mixed with 4X SDS-PAGE sample buffer 
and DTT reducing agent (to 50 nmol/l) and were heated to 
95˚C for 5 min. Equal amounts of samples were loaded onto 
SDS-PAGE gel and subsequently transferred to PVDF (poly-
vinylidene difluoride) membranes (Bio-Rad Laboratories). 
The membrane was washed three times for 45 min with PBST 
and then incubated with the secondary antibody diluted with 
5% milk in PBST for 1 h. After further washing the membrane 
three times for 45 min with PBST, antibody binding was deter-
mined by a chemiluminescence detection kit and densitometry 
was measured by Fluor ChemImager (Alpha Innotech, San 
Leandro, CA, uSA).
Statistical analysis. All experiments were independently 
repeated at least three times. Data are means ± SD. Student's 
t-test was applied for differences between groups using SPSS 
software. Significant differences among groups were calcu-
lated and P<0.05 was viewed as statistically significant.
Results
Effect of SFN on cell proliferation and viability in HUVECs 
and PVC. As a viable and adequate population of HuVECs 
and PVC is essential for angiogenesis, the effect of SFN on cell 
proliferation and viability of both cell types were measured 
by treating the cells with SFN over a range of concentrations 
(0.625-160 µM) for 24 and 48 h followed by an MTT assay. 
At low doses, from 0.625 to 5 µM, SFN has no toxic effect 
on cell viability. SFN at 2.5 µM (24 h) promoted cell prolif-
eration to 116 and 136% in HuVECs and PVC, respectively 
(Fig. 1). However, a dose-dependent effect on cell viability 
was observed following treatments with SFN between 20 
and 160 µM, i.e. cell viability decreased to 83.8% and <10% 
respectively, IC50, 46.7 µM. In parallel, the influence of SFN on 
PVC was also determined, and a similar dose-dependent effect 
on cell viability was observed. In both cell types, there was no 
significant difference in cell viability after exposure to 10 µM 
SFN at 24 and 48 h although the PVCs are slightly more sensi-
tive to SFN with IC50, 32.4 µM. Based on these results, 10 µM 
SFN was chosen as an optimum dosage for the tube formation 
experiments and 1-20 µM were used for mechanistic studies.
SFN suppresses capillary formation in 3D collagen model of 
HUVECs and PVC co-culture. The tube formation assay in 3D 
collagen gel is a well-established procedure for the evaluation 
of angiogenic capacities. To detect the angiogenic effect of 
SFN, a co-culture model consisting of HuVECs and pericytes 
was used to mimic more realistically the in vivo angiogenic 
process. Angiogenic growth factors were present in the 
collagen matrix in order to more closely represent a tumour 
microenvironment to promote capillary-like tube formation 
through ECs alignment with supporting pericytes. In the 
vehicle control (0.1% DMSO), HuVECs and pericytes formed 
robust capillary structures. The addition of SFN to the growth 
medium of the co-culture collagen gel, led to a concentration-
dependent disruption of the tube structure. The formation 
of tube structures were only partially inhibited at moderate 
SFN concentrations (2.5-10 µM) whilst higher dosages 
(20 µM) completely inhibited the formation of tube structures 
(Fig. 2A). Notably, SFN at low concentrations from 0.625 to 
1.25 µM promoted the formation of tubes by 115-120% of the 
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control, i.e. total tube length was 3.86 mm/mm2 in control 
and 4.69 mm/mm2 in SFN (1.25 µM) treated cells (Fig. 2B). 
Immunostaining of control cells with anti-CD31 and DAPI 
showed capillary-like morphology in the untreated HuVECs 
and PVCs (Fig. 2C).
Effect of SFN on VEGF and VEGFR2 expression. To evaluate 
whether SFN inhibits VEGF expression, PVC were cultured 
in EGM2 medium for 24 h followed by a dose-dependent 
(1.25-20 µM), or a time course (0-24 h) of treatment with 
SFN (10 µM). Western blot analysis for VEGF protein 
expression demonstrated that SFN inhibits VEGF in PVC in 
a dose- and time-dependent manner (Fig. 3A and B). SFN 
inhibited VEGF expression to 60 and 30% of the control 
after the treatments with 5 and 20 µM SFN (24 h), respec-
tively. An inhibitory effect of 10 µM SFN was also observed 
after 3 h (70% of control), 12 h (48% of control) and 24 h 
(36% of control) treatment (Fig. 2B). However, VEGF was 
not at detectable level in similarly treated HuVECs (data 
not shown). To further investigate VEGF and its receptor 
signalling pathway, the effect of SFN on VEGFR2 protein 
expression was determined. Not surprisingly, PVCs do not 
Figure 1. Effect of SFN on cell viability in HuVECs and pericytes. Dose-dependent effect of SFN on cell viability in (A) HuVECs and (B) pericytes. 
Exponentially growing cells were treated with SFN (0-160 µM) for 24 and 48 h. Cell viability was measured by MTT assay. Each concentration was tested in 
quadruplicate and the experiment was repeated twice. Results were present as % of control. *P<0.05 compared with control.
Figure 2. Effect of SFN on capillary formation in 3D culture of HuVECs and pericytes. (A) Representative images show dose-dependent effect of SFN for 
24 h in the 3D tube model of co-culture HUVECs with pericytes (magnification, x5). Images were taken by optical micrographs after 24 h. (B) Line chart 
represents cumulative tube length of 3D co-culture model exposed to SFN (0-20 µM). (C) Morphology of capillary-like structures in untreated control. Data 
are representative of three independent experiments. *P<0.05; **P<0.01.
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express detectable levels of VEGFR2 (data not shown), whilst 
HUVECs showed a significant upregulation of VEGF-R2 
level after SFN treatment (Fig. 3C and D).
Differential regulation of HIF signalling pathway after SFN 
exposure. HIF pathway is an important signaling pathway for 
HIF secretion especially in tumour micro-environments. In 
the present study, HIF-1α, PHD1 and PHD2 protein expres-
sion in both HUVECs and PVC were quantified by western 
blot assay. Both cell types were treated with 10 µM SFN for 
different time periods (1, 3, 6, 12 and 24 h) and HIF-1α and 
the relative expressions in both types of cells were measured. 
SFN increased HIF-1α expression in both cell types, i.e. 2.0- 
to 2.4-fold in HuVECs and 4.2-2.7-fold in PVC at 12 and 24 h, 
respectively (Fig. 4A and B). As expected, the effect of SFN 
on the expression of PHD1 was suppressed by SFN, 30% in 
HuVECs and 40% in pericytes at 24 h of treatment. Moreover, 
increasing SFN concentration in HuVECs from 1.25 to 20 µM 
for 24 h, had no significant effect on PHD1 protein expression, 
but again increased HIF-1α expression (Fig. 4C). Activation of 
HIF-1α may associate with the low-dose promotion effect of 
SFN on cell growth.
Figure 3. Effect of SFN on VEGF and VEGFR2 expression in HUVECs and pericytes. (A) Pericyes were treated with SFN (1.25-20 µM) for 24 h; Control 
was DMSO at 0.1%. (B) Cells were treated with SFN 10 µM for 1, 3, 6, 12 and 24 h. Time 0 was control (DMSO 0.1%). All pericytes were cultured in DMEM 
medium then replaced by EGM2 medium 24 h before SFN treatments. (C) HUVECs were treated with SFN (1.25-20 µM) for 24 h; SFN 0 was control (DMSO 
0.1%). (D) HuVECs were treated with SFN 10 µM for 1, 3, 6, 12 and 24 h. Equal amounts of cellular protein (80 µg) were loaded, and resolved by SDS/10% 
PAGE and western blot analysis. Data are representative of three independent experiments.
Figure 4. Effect of SFN on HIF-1α, PHD1 and PHD2 expression in HuVECs and pericytes. (A) HuVECs were treated with SFN (10 µM) and whole protein 
was isolated at 1, 3, 6, 12 and 24 h. Time 0 cells was treated with DMSO (0.1%) as control. (B) HIF-1α, PHD1 and PHD2 were detected in pericytes after 
exposure to SFN (10 µM for 1 to 24 h) using western blot analysis. Cells grown to ~50-60% confluence in DMEM medium, then replaced by EGM2 medium 
and incubated for further 24 h before SFN treatment. In the DMEM only group, cells were cultured and treated with SFN (10 µM). (C) HuVECs were treated 
with SFN (1.25-20 µM) for 24 h. Data are representative of three independent experiments.
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Effect of SFN on TrxR1 expression. Inhibition of thioredoxin 
reductase (TrxR1) has been shown to regulate angiogenesis by 
increasing endothelial cell-derived VEGF (39). SFN increased 
TrxR1 expression in both HuVECs and PVC dose- and 
time-dependently, i.e. SFN at 10 µM induced TrxR1 2.8- and 
3.7-fold in HuVECs (Fig. 5A and B) and PVC (Fig. 5C and 
D), respectively. TrxR1 plays an important role in SFN inhi-
bition of angiogenesis. Knockdown of TrxR-1 abolished the 
downregulation of PHD1 by SFN treatment (10 µM, 24 h), 
suggesting a deficiency of TrxR-1 may cause the accumula-
tion of PHD1. However, knockdown of TrxR1 only attenuated 
~20% of the SFN-inhibited tube formation (data not shown) 
suggesting that the inhibition of tube formation by SFN is only 
partly TrxR1-dependent.
Discussion
In the present study, we demonstrated that SFN exhibited 
differential effect on the regulation of angiogenesis in ECs 
and pericytes which may interrupt the crosstalk mechanism 
between them leading to reduced angiogenic capacity. 
Conventional planar cultures fail to recreate the in vivo 
physiology of the microvasculature with respect to 3D 
geometry (lumens and axial branching points) and interac-
tions of endothelium with perivascular cells, extracellular 
tissue and blood flow (40,41). There is strong evidence that 
the 3D in vitro model consisting of multiple stromal cells 
is not only cheaper but also provides quicker results than 
animal models. Additionally, 3D models are more analogous 
to pathological progression of angiogenesis than 2D cell 
culture models. Herein, we set up a 3D collagen model of 
HuVECs and pericytes in co-culture with growth factors to 
closely mimic the angiogenesis process in vivo microenvi-
ronment, and to allow the detection of the effects of dietary 
bioactives such as SFN, and the delineation of the molecular 
mechanisms of SFN in the interactions between HuVEC 
and PVCs.
SFN affected the network structure of neovascularization, 
causing disruption at concentrations >5 µM dose- and time-
dependently. A marked increase in microvessel formation 
at lower doses between 0.625-1.25 µM was also observed. 
This bell-shaped effect (hormesis) is common in anticancer 
agents (15,42) which suggests the importance of maintaining 
the SFN at high concentrations (>5 µM) for cancer chemo-
prevention or treatment. These tube formation results were 
consistent with the cell viability data that showed that SFN 
inhibited the growth of ECs at concentrations of 5-20 µM 
while at low concentrations of 0.625-2.5 µM, SFN promoted 
cell growth. Our findings suggest that the multi-targeted effect 
of SFN in EC-pericyte coculture model and on proliferation 
of ECs, demonstrates that its mechanism of action is complex. 
The biphasic effects of SFN on angiogenesis indicate that 
lower concentrations may provide benefit in conditions where 
the formation of an inadequate number of new blood vessels 
prevent an adequate blood supply, such as many cardiovas-
cular diseases. In contrast, high concentrations of SFN (in the 
present study, 5-20 µM) are needed for the anti-angiogenic 
effects.
At the level of protein expression, SFN treatment was 
found to inhibit VEGF secretion from pericytes but upregu-
late VEGF receptor-2 expression in ECs. VEGF, one of the 
major angiogenesis factors, is induced in growing tumours 
and stimulates EC proliferation and migration primarily 
through the VEGFR2 (Flk1/KDR) pathway (43). HIF-1 
is overexpressed in many human cancers and it regulates 
the expression of VEGF. Yao et al (23) demonstrated the 
inhibitory effect of SFN on HIF-1α and VEGF expression in 
human SCCs and prostate cancer cells via multiple pathways. 
Bertl et al (31), reached a similar conclusion in their study. 
The HIF pathway is also responsible for acquisition of resis-
tance against anti-VEGF therapy. Our results contradict some 
other findings that SFN was found to have unique character 
by activating HIF-1α pathway in both HuVECs and PVC but 
supressing VEGF expression in PVC. The exact mechanism 
is not clear but early research has revealed other transcription 
factors are also involved in VEGF expression, such as Sp1/
Sp3, AP2, Egr-1 and STAT-2 (44). For example, SFN was 
found to be able to inhibit STAT and SP1 pathways (45,46). 
Our finding may suggest that SFN has a potential role in 
attenuating anticancer resistance.
Figure 5. Effect of SFN on TrxR1 protein expression in HuVECs and pericytes. (A) HuVECs were treated with SFN (1.25-20 µM) for 24 h. (B) HuVECs 
were treated with SFN 10 µM for different times (1, 3, 6, 12 and 24 h). (C) Pericytes were treated with SFN (1.25-20 µM) for 24 h. (D) Pericytes were treated 
with SFN (10 µM) for 1, 3, 6, 12 and 24 h. All pericytes were cultured in DMEM medium (50-60%) until being replaced by EGM2 medium and incubated for 
24 h before SFN treatment for another 24 h. 
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TrxR1, an Nrf2-driven selenoprotein, was upregulated by 
SFN and may increase the anti-oxidant and redox regulation 
capability. The increase in TrxR1 expression following SFN 
treatment (10 µM) was found time- and dose-dependently 
(Fig. 4).
TrxR1 is involved in cell proliferation, redox regulation 
of gene expression and signal transduction, protection against 
oxidative stress, anti-apoptotic functions and regulation of the 
redox state of the extracellular environment (47). upregulation 
of TrxR1 plays a role in protection against free-radical mediated 
cell death (48). In this study, knockdown of TrxR1 attenuated 
~20% SFN inhibition of tube formation, and co-treatment 
of HuVECs/PVC with SFN and N-acetylcysteine (NAC) at 
2 mM abolished the promoting effect of low dose SFN on 
tube formation (data not shown). This indicates the involve-
ment of reactive oxygen species (ROS) (49,50). However, 
excessive ROS production may play a role in microvascular 
instability (51).
It is well accepted that angiogenesis is a critical, rate-
limiting step in the development of cancers and its inhibition 
suppresses tumour growth, progression and metastases. 
Antiangiogenic therapy using dietary compounds repre-
sents a new cost-effective approach to the early intervention 
and prevention of cancer (52). There are many natural and 
synthetic antioxidants such as curcumin, tea polyphenols and 
vitamins E and C that possess anti-angiogenic activities (53) 
and there is significant potential in the further investigation 
of their interactions in modulation of angiogenesis. Dietary 
isothiocynates such as SFN, derived from glucoraphanin from 
cruciferous vegetables, have attracted much attention for their 
potential to prevent various types of cancers. SFN may protect 
endothelium from oxidative stress by inducing TrxR1 expres-
sion and activity and also by suppressing the activation of 
MAPKs (38,54). When 5-20 µM SFN was used, the expression 
of TrxR1 was increased and this is associated with resistance to 
inflammation (55). The downregulation of angiogenic signal-
ling pathways by SFN could offer a new therapeutic strategy 
in suppressing malignant tumour progression, especially if 
multiple molecules were targeted and suppressed in cells 
responsive to SFN potentiated modulation of the angiogenic 
process. The results from the present study strongly indicate 
a potential role of SFN at higher doses in anti-angiogenesis 
cancer therapy. The action of SFN in targeting HIF, PHD and 
VEGF in the interplay between ECs and pericytes may shed 
insights into new treatment strategies. Therefore, the thera-
peutic potential of SFN as a potential alternative anti-VEGF 
agent in chemoprevention is worthy of further exploration in 
animal models and small scale human trials.
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